ACADEMIC STAFF

pic2026

Contact Information

Email:
shi_ruoyu@nuhs.edu.sg(opens in new tab)

Other Information

Shi Ruoyu

M.D, FRCPath (UK)
CONSULTANT, NUH

RESEARCH FOCUS

        • Immunotherapy related pathology
        • Biomarker development in liver as well as other types of cancer

BIOGRAPHY​

Dr Ruoyu Shi received his Doctor of Medicine degree from Fudan University, China. He completed his pathology residency training under the SingHealth Residency Programme and obtained his Fellowship of the Royal College of Pathologists (United Kingdom) in 2020. Prior to joining the Department of Pathology at National University Hospital, he worked at Singapore General Hospital and KK Women’s and Children’s Hospital. His interests in diagnostic pathology services include gastrointestinal and hepatobiliary pancreatic pathology, genitourinary pathology, and gynaecological pathology. He is particularly interested in applying new technologies and translational medicine research outcomes to promote pathology service in the diagnosis and prognosis of disease, education and providing new evidence to guide clinical management.

Awards

    • NUHS Nurturing Clinician Scientist Program 3.0 2026
    • Singhealth Publish! Award 2024
    • Singhealth Publish! Award 2023
    • European Society of Pathology Giordano Fellowship 2023 Awardee
    • 2nd European Society of Pathology Academy 2022 Awardee.

Recent Publications

    • Immune-related pathologic response (irPR) features and immunotherapeutic response score (ITRS) predict survival following neoadjuvant/conversion combined immunotherapy in intrahepatic cholangiocarcinoma.
      Shi R, Sang Y, Chua CZX, Yang L, Iqbal J, Loh PWX, Wu G, Luo R, Koh YX, Fan J, Gao Q, Xia H, Zhou J, Zhu K. (First author)
      Virchows Arch. 2026 Jul 13. doi: 10.1007/s00428-026-04640-w. Epub ahead of print.

    • Immune-Related Pathological Features and Predictive Score in Intrahepatic Cholangiocarcinoma Treated With Combined Conversion Immunotherapy.
      Chen W, Sang Y, Soon GST, Chew EJC, Wu G, Lin X, Luo R, Gao Q, Zhou J, Xia H, Zhu K, Shi R. (Last author)
      Mod Pathol. 2026 Jun 9;39(8):101020. doi: 10.1016/j.modpat.2026.101020. Online ahead of print.

    • Histopathologic grading of residual tumor predicts survival of intrahepatic cholangiocarcinoma patients treated with neoadjuvant therapy: Major pathologic response and its clinical significance.
      Gaohua Wu, Xiufen Chen, Rongkui Luo, Ye Xin Koh, Tony Kiat Hon Lim, Valerie Chew, Jian Zhou, Jia Fan, Qiang Gao, Kai Zhu, Ruoyu Shi (Last author)
      American Journal of Surgical Pathology. 2025 Jun 1;49(6):578-587.

    • Immune and histopathological biomarkers for prognosis and neoadjuvant immunotherapy response in intrahepatic cholangiocarcinoma.
      Jannah M. Nasir, Edwin J. C. Chew, Kai Zhu, Gaohua Wu, Rongkui Luo, Wei-Qiang Leow, Tony K H Lim, Qiang Gao, Ruoyu Shi, Valerie Chew, Jian Zhou. (Co-correspondent author)
      Liver Cancer. 2025 Jul 18. doi: 10.1159/000547326. Online ahead of print

    • Tumor budding in pre-neoadjuvant biopsy and post-neoadjuvant resection specimens is associated with poor prognosis in intrahepatic cholangiocarcinoma-a cohort study of 147 cases by modified ITBCC criteria.
      Wu G, Luo R, Xu Q, Yang L, Xia H, Chew V, Koh YX, Chang KTE, Zhou J, Fan J, Gao Q, Shi R, Zhu K. (Co-correspondent author)
      Virchows Arch. 2024 Nov;485(5):913-923.

    • Image analysis for bright-field HER2 in situ hybridization: validation for clinical use.
      Shi R, Pinto JC, Rienda I, Caie P, Eloy C, Polónia A. (First author)
      Virchows Arch. 2025 Mar;486(3):541-549.

    • Intraoperative Frozen Section Evaluation of Ovarian Sex Cord-Stromal Tumours and Their Mimics: A Study of 121 Cases with Emphasis on Potential Diagnostic Pitfalls.
      Zitong Z, Shing LW, Jason KSC, Joella XA, Gek HL, Junsiyuan L, Lixia Z, Hui MC, Nye TN, Chee LC, Puay HT, Ruoyu S. (Last and correspondent author)
      Pathology. 2024 Oct;56(6):842-853.

    • Prognostic value of tumor budding in urothelial carcinoma: A meta-analysis and systematic review.
      Shi R, Le Tan MT, Lim GH, Du J, Zhang L, Zeng L, Tan PH. (First author)
      Lab Invest. 2023 June;103(6):100136.

    • Mass-forming immunoglobulin G4-related disease shows indolent clinical course after surgical resection, clinicopathological analysis of a series of 15 cases.
      Shi R, Farah BL, Xu C, Yeong JPS, Kuick CH, Goh JY, Chang KTE, Takano A. (First author)
      Virchows Arch. 2022 Feb;480(2):383-391. doi: 10.1007/s00428-021-03216-0.

  •  
Scroll to Top